Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Nagoya City University78 enrolled

Overview

To evaluate the visual outcome, number of injections and visits, and the effect of mental status of a treat and extend regimen in managing neovascular age-related macular degeneration with intravitreal ranibizumab.

Treat and Extend Regimen (TER) may contribute to the improvement to a patients' mentality, since the treatment intervals are extended if there were no signs of recurrence. Therefore, we have planned to examine the psychological impact of TER using Hospital Anxiety and Depression Scale (HADS), in addition to the improvement of visual acuity and central retinal thickness.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Neovascular Age-related Macular Degeneration

Interventions

Intraviteal Ranibizumab 0.5mgDRUG

Intraviteal Ranibizumab 0.5mg

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent form * Male or female of aged 50 years or older * Typical AMD and PCV patients * BCVA of 24 letters or over Exclusion Criteria: * Total lesion area of \>12 DA or \>30.5 mm2 * The existence of subretinal hemorrhage area constituting ≥50% of total lesion area * The existence of scar or fibrosis area constituting ≥50% of total lesion area * The existence of RPE tear * Prior treatment for wet AMD * History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD * The pregnant or lactating woman

Locations (2)

Sugita Eye Hospital

Nagoya, Aichi-ken, Japan

Nagoya City Univsersity

Nagoya, Aichi-ken, Japan

Outcomes

Primary Outcomes

Visual acuity

Time frame: One Year

Secondary Outcomes

central foveal thickness

Time frame: One and two years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.